Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target

Aldeyra Therapeutics is viewed favorably because Reproxalap has generated compelling late-stage efficacy across nine adequate and well-controlled clinical trials, with five achieving all multiplicity-controlled primary endpoints and several showing rapid activity on dry eye redness and symptoms. The company’s strategy of escalating the March 16, 2026 CRL through a Formal Dispute Resolution Request to the FDA’s Office of New Drugs reflects confidence that the totality of evidence, including two positive chamber trials and a supportive field trial, can overcome regulatory skepticism. Beyond Reproxalap, its first-mover RASP-scavenging platform and pipeline across large underserved indications such as dry eye disease and allergic conjunctivitis, with >15M and >30M diagnosed U.S. patients respectively, support a longer-term growth case.

Aldeyra Therapeutics is facing a deeply challenged regulatory profile because reproxalap has now received multiple CRLs, including on April 3, 2025 and again today, with the FDA citing lack of substantial evidence of efficacy, inconsistent study results, and methodological concerns such as baseline imbalances. Although the company pointed to a chamber trial that met its primary endpoint with ocular discomfort reduction (P=0.002) and used that data in its June 2025 resubmission, the FDA’s later request for the field trial clinical study report and extension to March 16, 2026 signaled ongoing uncertainty rather than conviction. Fundamentally, the negative outlook reflects repeated inability to convert late-stage development into a convincing approval package, leaving the company’s lead asset and commercialization prospects highly impaired.